UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000033412
Receipt number R000038094
Scientific Title Investigation of the effects of open-label placebos on patients with chronic low back pain
Date of disclosure of the study information 2018/07/17
Last modified on 2021/01/17 10:05:41

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Investigation of the effects of open-label placebos on patients with chronic low back pain

Acronym

Trial of open-label placebos to patients with chronic low back pain

Scientific Title

Investigation of the effects of open-label placebos on patients with chronic low back pain

Scientific Title:Acronym

Trial of open-label placebos to patients with chronic low back pain

Region

Japan


Condition

Condition

Chronic low back pain

Classification by specialty

Orthopedics

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The aim of this study is to investigate the efficacy and its substantivity on patients with chronic low back pain.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2


Developmental phase

Not applicable


Assessment

Primary outcomes

Pain intensity:Numerical rating scale.
Pain disability:Roland-Morris Disability Questionnaire.

Key secondary outcomes

Timed up and go test
Subjective satisfaction scale


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification

YES

Dynamic allocation

NO

Institution consideration

Institution is not considered as adjustment factor.

Blocking

NO

Concealment

Numbered container method


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Behavior,custom

Interventions/Control_1

Open label placebo capsule with sufficient information
Taking 2 capsules/time, morning & evening /day with confirming the effect of placebo
Outcomes are assessed at baseline, 3 week and 3 months

Interventions/Control_2

Usual treatment
Outcomes are assessed at baseline, 3 week and 3 months

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

100 years-old >

Gender

Male and Female

Key inclusion criteria

Chronic low back pain
1)Pain is lasting for more than 6 months
2)Subjective pain magnitude is at least 3 out of 0-10 numerical rating scale

Key exclusion criteria

1)No wish toparticipation
2)Pain radiating into lower leg
3)On going treatment of malignant tumor, spinal fractures and spinal infections
4)Autoimmune diseases
5)Spondyloarthropathy
6)Elderly aged 75 years and older whose Tscore of DXA is lower than 2.5
7)Histories of fragile spinal fractures
8)Histories or use of steroids for more than 3 months.
9)Spinal kyphosis or spinal scoliosis whose cobb angle is over 30 degree
10)Within 3 months after thoracic or lumbar surgeries
11)Taking medicaion associated with dementia
12)Suspicious cognitive disorder
13)Judged ineligible by the researchers

Target sample size

52


Research contact person

Name of lead principal investigator

1st name Tatsunori
Middle name
Last name Ikemoto

Organization

Aichi medical university

Division name

Department of Orthopedic Surgery

Zip code

480-1195

Address

1-1 Yazako Karimata, Nagakute, Aichi

TEL

0561631087

Email

tatsunon31-ik@umin.ac.jp


Public contact

Name of contact person

1st name Tatsunori
Middle name
Last name Ikemoto

Organization

Aichi medical university

Division name

Department of Orthopedic Surgery

Zip code

480-1195

Address

1-1 Yazako Karimata, Nagakute, Aichi

TEL

0561631087

Homepage URL


Email

tatsunon31-ik@umin.ac.jp


Sponsor or person

Institute

Department of Orthopedic Surgery, Aichi Medical University

Institute

Department

Personal name



Funding Source

Organization

Department of Orthopedic Surgery, Aichi Medical University

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Aichi Medical University

Address

1-1 Yazako Karimata, Nagakute, Aichi, 480-1195, Japan.

Tel

0561-62-3311

Email

tatsunon31-ik@umin.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

愛知医科大学病院(愛知県)


Other administrative information

Date of disclosure of the study information

2018 Year 07 Month 17 Day


Related information

URL releasing protocol


Publication of results

Published


Result

URL related to results and publications

https://www.hindawi.com/journals/prm/2020/6636979/

Number of participants that the trial has enrolled

52

Results

The present study investigated whether the OLP+TAU treatment was effective for Japanese patients with CLBP under the assumption of equal efficacy as in the previous reports. Our results revealed that OLP+TAU showed no significant superior benefit in comparison with TAU alone after 3- and 12-week interventions for Japanese patients with CLBP although significant improvements in functional disability were obtained in both groups at week 12.

Results date posted

2021 Year 01 Month 17 Day

Results Delayed


Results Delay Reason


Date of the first journal publication of results

2020 Year 12 Month 28 Day

Baseline Characteristics

Of the 52 patients, 32 (68.2%) were women and the mean age (SD) was 66.8 (13.4) years.

Participant flow

Between August 2018 and March 2020, 70 patients with CLBP were initially referred to as the primary investigator, and 18 patients were excluded due to the eligibility criteria.

Adverse events

Adverse events were not observed in the study participants.

Outcome measures


Plan to share IPD

The data used to support the findings of this study are available from the corresponding author upon request.

IPD sharing Plan description



Progress

Recruitment status

Main results already published

Date of protocol fixation

2018 Year 07 Month 13 Day

Date of IRB

2018 Year 07 Month 13 Day

Anticipated trial start date

2018 Year 08 Month 01 Day

Last follow-up date

2020 Year 03 Month 31 Day

Date of closure to data entry

2020 Year 08 Month 20 Day

Date trial data considered complete

2020 Year 08 Month 20 Day

Date analysis concluded

2020 Year 09 Month 28 Day


Other

Other related information

https://www.hindawi.com/journals/prm/2020/6636979/


Management information

Registered date

2018 Year 07 Month 17 Day

Last modified on

2021 Year 01 Month 17 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000038094


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name